, proposition des différents schémas thérapeutiques pour le Génotype 5 et 6 (D'après l'AFEF 05/2015) Bibliographie : 1. Lindenbach BD. Virion Assembly and Release, vol.15, pp.199-218, 2013.

S. Ishida, M. Kaito, M. Kohara, K. Tsukiyama-­-kohora, N. Fujita et al.,

, Hepatitis C virus core particle detected by immunoelectron microscopy and optical rotation technique, Hepatol Res Off J Jpn Soc Hepatol. juill, vol.20, issue.3, pp.335-382, 2001.

L. Cocquerel, S. Duvet, J. C. Meunier, A. Pillez, R. Cacan et al., The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum, J Virol. avr, vol.73, issue.4, pp.2641-2650, 1999.

M. Régeard, C. Lepère, M. Trotard, P. Gripon, L. Seyec et al., Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle, FEBS J. sept, vol.274, issue.18, pp.4705-4723, 2007.

B. D. Lindenbach and C. M. Rice, Unravelling hepatitis C virus replication from genome to function, Nature. 18 août, vol.436, issue.7053, pp.933-941, 2005.

R. Suzuki, T. Suzuki, K. Ishii, Y. Matsuura, and T. Miyamura, Processing and Functions of Hepatitis C Virus Proteins, Intervirology, vol.42, issue.2-­-3, pp.145-52, 1999.

F. Penin, J. Dubuisson, F. A. Rey, D. Moradpour, and J. Pawlotsky, Structural biology of hepatitis C virus, Hepatol Baltim Md. janv, vol.39, issue.1, pp.5-19, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00313693

R. Brown, A. W. Tarr, C. P. Mcclure, V. S. Juttla, N. Tagiuri et al., Cross-­genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes, J Gen Virol. févr, vol.88, pp.458-69, 2007.

S. Griffin, L. P. Beales, D. S. Clarke, O. Worsfold, S. D. Evans et al., The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. janv, vol.535, issue.1-­-3, pp.34-42, 2003.

A. Sakai, M. S. Claire, K. Faulk, S. Govindarajan, S. U. Emerson et al., The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-­-specific sequences, Proc Natl Acad Sci, vol.100, issue.20, pp.11646-51, 2003.

B. Boson, O. Granio, R. Bartenschlager, and F. Cosset, A Concerted Action of Hepatitis C Virus P7 and Nonstructural Protein 2 Regulates Core Localization at the Endoplasmic Reticulum and Virus Assembly, PLoS Pathog. 21 juill, vol.7, issue.7, p.1002144, 2011.

P. Tedbury, S. Welbourn, A. Pause, B. King, S. Griffin et al., The subcellular localization of the hepatitis C virus non-­-structural protein NS2 is regulated by an ion channel-­-independent function of the p7 protein, J Gen Virol. avr, vol.92, pp.819-849, 2011.

M. Hijikata, H. Mizushima, T. Akagi, S. Mori, N. Kakiuchi et al., Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus, J Virol. août, vol.67, issue.8, pp.4665-75, 1993.

S. Welbourn, R. Green, I. Gamache, S. Dandache, V. Lohmann et al.,

, Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication, J Biol Chem. 19 août, vol.280, issue.33, pp.29604-29615, 2005.

C. T. Jones, C. L. Murray, D. K. Eastman, J. Tassello, and C. M. Rice, Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus, J Virol. août, vol.81, issue.16, pp.8374-83, 2007.

T. Phan, R. Beran, C. Peters, I. C. Lorenz, and B. D. Lindenbach, Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1-­-E2 Glycoprotein and NS3-­-NS4A Enzyme Complexes, J Virol. sept, vol.83, issue.17, pp.8379-95, 2009.

C. De-la-fuente, Z. Goodman, and C. M. Rice, Genetic and functional characterization of the N-­-terminal region of the hepatitis C virus NS2 protein, J Virol. avr, vol.87, issue.8, pp.4130-4175, 2013.

K. Morikawa, C. M. Lange, J. Gouttenoire, E. Meylan, V. Brass et al., Nonstructural protein 3-­-4A: the Swiss army knife of hepatitis C virus, J Viral Hepat. mai, vol.18, issue.5, pp.305-320, 2011.

C. Failla, L. Tomei, D. Francesco, and R. , An amino-­-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A, J Virol. mars, vol.69, issue.3, pp.1769-77, 1995.

B. Wölk, D. Sansonno, H. G. Kräusslich, F. Dammacco, C. M. Rice et al., Subcellular localization, stability, and trans-­-cleavage competence of the hepatitis C virus NS3-­-NS4A complex expressed in tetracycline-­-regulated cell lines, J Virol. mars, vol.74, issue.5, pp.2293-304, 2000.

M. Lundin, M. Monné, A. Widell, V. Heijne, G. Persson et al., Topology of the membrane-­-associated hepatitis C virus protein NS4B, J Virol. mai, vol.77, issue.9, pp.5428-5466, 2003.

D. Egger, B. Wölk, R. Gosert, L. Bianchi, H. E. Blum et al., Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex, J Virol. juin, vol.76, issue.12, pp.5974-84, 2002.

V. Brass, E. Bieck, R. Montserret, B. Wölk, J. A. Hellings et al., An amino-­terminal amphipathic alpha-­-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A, J Biol Chem. 8 mars, vol.277, issue.10, pp.8130-8139, 2002.
URL : https://hal.archives-ouvertes.fr/hal-00313705

T. L. Tellinghuisen, J. Marcotrigiano, A. E. Gorbalenya, and C. M. Rice, The NS5A protein of hepatitis C virus is a zinc metalloprotein, J Biol Chem, vol.279, issue.47, pp.48576-87, 2004.

T. L. Tellinghuisen, J. Marcotrigiano, and C. M. Rice, Structure of the zinc-­-binding domain of an essential component of the hepatitis C virus replicase, Nature. 19 mai, vol.435, issue.7040, pp.374-383, 2005.

D. Ross-­-thriepland, Y. Amako, and M. Harris, The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release, J Gen Virol. 1 mai, vol.94, pp.1009-1027, 2013.

N. Appel, M. Zayas, S. Miller, J. Krijnse-­-locker, T. Schaller et al., Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly, PLoS Pathog. 28 mars, vol.4, issue.3, p.1000035, 2008.

K. J. Blight, A. A. Kolykhalov, and C. M. Rice, Efficient initiation of HCV RNA replication in cell culture, Science. 8 déc, vol.290, issue.5498, pp.1972-1976, 2000.

K. J. Blight, J. A. Mckeating, and C. M. Rice, Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication, J Virol. déc, vol.76, issue.24, pp.13001-13015, 2002.
DOI : 10.1128/jvi.76.24.13001-13014.2002

URL : https://jvi.asm.org/content/76/24/13001.full.pdf

K. J. Blight, J. A. Mckeating, J. Marcotrigiano, and C. M. Rice, Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture, J Virol. mars, vol.77, issue.5, pp.3181-90, 2003.

V. Lohmann, S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager, Viral and cellular determinants of hepatitis C virus RNA replication in cell culture, J Virol. mars, vol.77, issue.5, pp.3007-3026, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00313699

N. Appel, T. Pietschmann, and R. Bartenschlager, Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain, J Virol. mars, vol.79, issue.5, pp.3187-94, 2005.

M. J. Evans, C. M. Rice, and S. P. Goff, Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication, Proc Natl Acad Sci U S A. 31 août, vol.101, issue.35, pp.13038-13081, 2004.
DOI : 10.1073/pnas.0405152101

URL : http://www.pnas.org/content/101/35/13038.full.pdf

P. Neddermann, M. Quintavalle, D. Pietro, C. Clementi, A. Cerretani et al., Reduction of Hepatitis C Virus NS5A Hyperphosphorylation by Selective Inhibition of Cellular Kinases Activates Viral RNA Replication in Cell Culture, J Virol. déc, vol.78, issue.23, pp.13306-13320, 2004.

D. Moradpour, V. Brass, E. Bieck, P. Friebe, R. Gosert et al., Membrane association of the RNA-­-dependent RNA polymerase is essential for hepatitis C virus RNA replication, J Virol. déc, vol.78, issue.23, pp.13278-84, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00313684

, Variabilité génétique du virus de l'hépatite C : implications cliniques, vol.29

. Disponible,

A. U. Neumann, N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley et al., Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-­-alpha therapy, Science, vol.282, issue.5386, pp.103-110, 1998.

C. Trépo, P. Merle, and F. Zoulim, Hépatites virales B et C [Internet

. Disponible,

J. C. Desenclos, Les infection par le virus de l'hépatite C dans le monde : importance en santé publique, modes de transmission et perspectives, Virologie. 1 juill, vol.7, issue.3, pp.177-91, 2003.

J. P. Messina, I. Humphreys, A. Flaxman, A. Brown, G. S. Cooke et al., Global Distribution and Prevalence of Hepatitis C Virus Genotypes, Hepatol Baltim Md. janv, vol.61, issue.1, pp.77-87, 2015.

P. Grob, The hepatitis C virus, 2002.

M. B. Zeisel, I. Fofana, S. Fafi-­-kremer, and T. F. Baumert, Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies, J Hepatol. 1 mars, vol.54, issue.3, pp.566-76, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00701487

E. Blanchard, S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson et al.,

, Hepatitis C Virus Entry Depends on Clathrin-­-Mediated Endocytosis, J Virol. juill, vol.80, issue.14, pp.6964-72, 2006.

J. Dubuisson, F. Helle, and L. Cocquerel, Early steps of the hepatitis C virus life cycle, Cell Microbiol. 1 avr, vol.10, issue.4, pp.821-828, 2008.

H. Barth, C. Schafer, M. I. Adah, F. Zhang, R. J. Linhardt et al., Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate, J Biol Chem, vol.278, issue.42, pp.41003-41015, 2003.

A. Cambi, M. Koopman, and C. G. Figdor, How C-­-type lectins detect pathogens, Cell Microbiol. avr, vol.7, issue.4, pp.481-489, 2005.

S. Molina, V. Castet, C. Fournier-­-wirth, -. Pichard, L. Garcia et al., The low-­-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus, J Hepatol. mars, vol.46, issue.3, pp.411-420, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00374413

F. Cosset, Entrée cellulaire du virus de l'hépatite C, Virologie. 1 mai, vol.10, issue.3, pp.179-91, 2006.

P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi et al., Binding of hepatitis C virus to CD81. Science, vol.282, pp.938-979, 1998.

M. J. Evans, T. Von-hahn, D. M. Tscherne, A. J. Syder, M. Panis et al., Claudin-­-1 is a hepatitis C virus co-­-receptor required for a late step in entry, Nature. 12 avr, vol.446, issue.7137, pp.801-806, 2007.

I. Benedicto, -. Molina, F. Bartosch, B. Cosset, F. Lavillette et al., The Tight Junction-­-Associated Protein Occludin Is Required for a Postbinding Step in Hepatitis C Virus Entry and Infection, J Virol. août, vol.83, issue.16, pp.8012-8032, 2009.

A. E. Smith and A. Helenius, How viruses enter animal cells, Science. 9 avr, vol.304, issue.5668, pp.237-279, 2004.

K. Tsukiyama-­-kohara, N. Iizuka, M. Kohara, and A. Nomoto, Internal ribosome entry site within hepatitis C virus RNA, J Virol. mars, vol.66, issue.3, pp.1476-83, 1992.

C. W. Kim and K. Chang, 55. ledinghen victorde. Histoire naturelle de l'infection par le virus de l'hépatite C. /data/revues/03998320/00260HS2/9, Clin Mol Hepatol. mars, vol.19, issue.1, pp.17-25, 2008.
URL : https://hal.archives-ouvertes.fr/in2p3-00023812

. Disponible,

J. Delfraissy, G. Pageaux, V. De-lédinghen, and D. Dhumeaux, Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C, 2014.

, Histoire naturelle de l'infection par le virus de l'hépatite C

E. , Disponible sur, 2015.

S. Broutin, V. Bouton, M. Sinègre, and P. Marcellin, Histoire naturelle et diagnostic de l'hépatite C, J Pharm Clin. 1 janv, vol.25, issue.1, pp.49-56, 2006.

. Cacoub-patrice, HAS. conditions de réalisation des tests rapides d'orientation diagnostique de l'infection à virus de l'immunodéficience humaine (VIH 1 et 2) et de l'infection à virus de l'hépatite C (VHC) en milieu médicosocial et associatif, Les manifestations extra-­-hépatiques au cours de l'infection par le virus de l'hépatite C [Internet]. Disponible sur

J. Trabut and . Le-score-métavir, Gastro Oncol Dig. 1 mai, vol.16, issue.3, pp.219-239, 2009.

N. , Place de la ponction-­-biopsie hépatique dans la prise en charge de l'hépatite chronique C. /data/revues/03998320/00260HS2/168, vol.29, 2008.

. Disponible,

V. De-lédinghen, T. Poynard, C. Wartelle, and E. Rosenthal, Évaluation non-­-invasive de la fibrose hépatique au cours de l'hépatite C, Gastroentérologie Clin Biol. mars, vol.32, issue.3, pp.90-95, 2008.

V. Leroy and M. Hilleret, évaluation de la fibrose hépatique, Gastro Oncol Dig. 1 juill, vol.12, issue.4, pp.251-260, 2005.

A. Fibrotest,

C. Hépato and -. Brousse, , p.25, 2014.

. Disponible,

C. Meffre, Prévalence des hépatites B et C en france en, InVS, 2004.

F. M. Averhoff, N. Glass, and D. Holtzman, Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States, Clin Infect Dis. 15 juill, vol.55, issue.1, pp.10-15, 2012.

D. Mennecier, Transmission de l'hépatite C

. Disponible,

B. Information-nc-for, U. Medicine, and . Of, Pike, vol.8600

. Disponible,

T. Asselah, H. Boudjema, C. Francoz, R. Sobesky, D. Valla et al., Hépatite C et transplantation hépatique

E. , DOROSZ guide pratique des médicaments 2015. 34ème édition. Pages 904, p.905, 2015.

S. Pol and H. Zylberberg, Interférons : des mécanismes d'action aux applications cliniques en hépatologie. Médecine Thérapeutique. 30 juin, vol.4, pp.323-354, 1998.

, DOROSZ guide pratique des médicaments 2015. 34ème édition. Pages 909, p.911

. Bianchi-vincent and . Médicaments, , p.145

B. Information-nc-for, U. Medicine, . Pike-8600-rockville, M. Bethesda, and U. Sofosbuvir-|-c22h29fn3o9p-­-pubchem,

. Disponible,

B. Information-nc-for, U. Medicine, . Pike-8600-rockville, M. Bethesda, U. Olysio et al.,

. Disponible,

. Negro, Nouveaux antiviraux actifs contre le virus de l'hépatite C

B. Information-nc-for, U. Medicine, . Pike-8600-rockville, M. Bethesda, U. Daclatasvir et al.,

. Disponible,

B. Information-nc-for, U. Medicine, . Pike-8600-rockville, M. Bethesda, U. Ledipasvir et al.,

. Disponible,

, Résumé des caractéristiques du produit de HARVONI.Annexe, vol.1

B. Information-nc-for, U. Medicine, . Pike-8600-rockville, M. Bethesda, U. Dasabuvir et al.,

. Disponible,

, Résumé des caractéristiques du produit de EXVIERA. Annexe, vol.1

B. Information-nc-for, U. Medicine, and . Of, Pike, vol.8600

. Disponible,

B. Information-nc-for, U. Medicine, and . Of, Pike, vol.8600

. Disponible,

I. M. Jacobson, F. Poordad, R. Firpi-­-morell, G. T. Everson, E. C. Verna et al., O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-­-infected patients with child-pugh class B cirrhosis (C-­-salt part A), J Hepatol. 1 avr, vol.62, pp.193-197, 2015.

P. Kwo, A Phase 3, randomised, open-­-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-­-naïve and-­-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-­-1 [Internet]. vienne, pp.22-26, 2015.

S. Pol, M. Bourliere, S. Lucier, V. De-ledinghen, F. Zoulim et al., LO3 : Safety and efficacy of the combination daclatasvir-­-sofosbuvir in HCV genotype 1-­mono-­-infected patients from the french observational cohort ANRS CO22 hepather*, J Hepatol. avr, vol.62, pp.258-267, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01162711

N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin et al., Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, N Engl J Med. 15 mai, vol.370, issue.20, pp.1889-98, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01690189

N. Afdhal, K. R. Reddy, D. R. Nelson, E. Lawitz, S. C. Gordon et al., Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection, N Engl J Med. 17 avr, vol.370, issue.16, pp.1483-93, 2014.

J. J. Feld, K. V. Kowdley, E. Coakley, S. Sigal, D. R. Nelson et al., Treatment of HCV with ABT-­-450/r-Ombitasvir and Dasabuvir with Ribavirin, N Engl J Med. 24 avr, vol.370, issue.17, pp.1594-603, 2014.

E. Lawitz, S. Flamm, J. C. Yang, P. S. Pang, Y. Zhu et al., O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-­-based regimens with ledipasvir/sofosbuvir for 24 weeks, J Hepatol. 1 avr, vol.62, p.192, 2015.

E. Lawitz, E. Gane, B. Pearlman, E. Tam, W. Ghesquiere et al., Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-­-5172) and elbasvir (MK-­-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-­-WORTHY): a randomised, open-­-label phase 2 trial, Lancet Lond Engl. 21 mars, vol.385, issue.9973, pp.1075-86, 2015.

E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-­-torres, T. Hassanein et al., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, N Engl J Med. 16 mai, vol.368, issue.20, pp.1878-87, 2013.

, Safety and Efficacy of Sofosbuvir-­-Containing Regimens for Hepatitis C: Real-­World Experience in a Diverse, Longitudinal Observational Cohort

. Disponible,

M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-­-torres, K. R. Reddy, T. Hassanein et al., Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, N Engl J Med. 16 janv, vol.370, issue.3, pp.211-232, 2014.

D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros et al., All-­-oral 12-­week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-­-3 phase III study, Hepatol Baltim Md. avr, vol.61, issue.4, pp.1127-1162, 2015.

C. Hezode and . Vdl, LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program, J Hepatol, vol.62, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01162768

G. R. Foster, S. Pianko, A. Brown, D. Forton, R. G. Nahass et al., Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-­-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-­-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection, Gastroenterology. nov, vol.149, issue.6, pp.1462-70, 2015.

H. Fontaine, C. Hezode, F. Zoulim, D. Samuel, M. Bourliere et al., LP28 : Efficacy of the oral sofosbuvir-­-based combinations in HCV genotype 4-­-mono-­-infected patients from the french observational cohort anrs CO22 hepather, J Hepatol. 1 avr, vol.62, p.278, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01162770

H. Experimental and . Drugs,

. Hivandhepatitis,

. Disponible,

C. Hézode, T. Asselah, K. R. Reddy, T. Hassanein, M. Berenguer et al., Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-­-naive and treatment-­-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-­-I): a randomised, open-­-label trial, The Lancet. juin, vol.385, issue.9986, pp.2502-2511, 2015.

S. Zeuzem, R. Ghalib, K. R. Reddy, P. J. Pockros, Z. B. Ari et al., Grazoprevir-­Elbasvir Combination Therapy for Treatment-­-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial, Ann Intern Med. 7 juill, vol.163, issue.1, pp.1-13, 2015.

S. Naggie, J. K. Rockstroh, M. Nelson, C. Katlama, J. Lalezari et al., Efficacy and safety of grazoprevir (MK-­-5172) and elbasvir (MK-­-8742) in patients with hepatitis C virus and HIV co-­-infection (C-­-EDGE CO-­-INFECTION): a non-­-randomised, open-­-label trial, Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-­-and HCV/HIV Co-­infected Patients, vol.2, pp.319-346, 2015.

A. Osinusi, E. G. Meissner, Y. Lee, D. Bon, L. Heytens et al., Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial, JAMA. 28 août, vol.310, issue.8, pp.804-815, 2013.

D. Echevarria, A. Gutfraind, B. Boodram, M. Major, D. Valle et al., Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-­-Up in Persons Who Inject Drugs in Metropolitan Chicago, PLoS ONE. 21 août, vol.10, issue.8, p.135901, 2015.

D. Guyader, Cours d'université de 2eme année de médecine Rennes 1 « Sémiologie biologique hépatique, 2009.

, Traitement de l'hépatite C après transplantation hépatique. /data/revues/03998320/00260HS2/231, vol.29

. Disponible,

P. Madiou-jean, Impact de la cinétique virale au cours du traitement de la récidive du VHC après TH (étude ANRS CO23 CUPILT), 2015.

J. Madiou and . Dcv-+-sof-dans-les-récidives-post-­-th, résultats d'un programme d'accès aux Etats-­-unis [Internet]. AASLD, 2015.

J. J. Feld, I. M. Jacobson, C. Hézode, T. Asselah, P. J. Ruane et al., Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection, N Engl J Med. 31 déc, vol.373, issue.27, pp.2599-607, 2015.

V. , combinaison d'antiviraux directs de nouvelle génération: ABT-­-493 et ABT-­-530 : 97%-­-100% de RVS12, pour les G1, non-­-cirrhotiques, naïfs ou répondeurs nuls à PEG RBV (SURVEYOR-­-1), 2015.

S. Chevaliez, Amélioration de la maladie hépatique après traitement par sofosbuvir et daclatasvir plus ribavirine chez des patients ayant une cirrhose sévère

. Nov;-san-francisco and . Disponible, AASLD, 2015.

P. Madiou-jean, Nouveaux antiviraux directs : quel impact sur les listes d'attente de TH ?, AASLD, 2015.